SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-017363
Filing Date
2023-05-15
Accepted
2023-05-15 16:15:43
Documents
17
Period of Report
2023-05-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 44001
2 ex10-1.htm EX-10.1 142931
3 ex10-2.htm EX-10.2 52907
4 ex99-1.htm EX-99.1 22009
5 ex99-1_001.jpg GRAPHIC 19245
  Complete submission text file 0001493152-23-017363.txt   544069

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE bctx-20230509.xsd EX-101.SCH 3955
7 XBRL DEFINITION FILE bctx-20230509_def.xml EX-101.DEF 26591
8 XBRL LABEL FILE bctx-20230509_lab.xml EX-101.LAB 36631
9 XBRL PRESENTATION FILE bctx-20230509_pre.xml EX-101.PRE 25215
11 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5452
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-40101 | Film No.: 23922552
SIC: 2834 Pharmaceutical Preparations